Thomas Walz - XSpray Pharma Chief Officer
| XSPRAY Stock | SEK 42.40 0.45 1.07% |
Insider
Thomas Walz is Chief Officer of XSpray Pharma AB
| Age | 63 |
| Phone | 46 87 30 37 00 |
| Web | https://www.xspraypharma.com |
XSpray Pharma Management Efficiency
The company has return on total asset (ROA) of (0.1448) % which means that it has lost $0.1448 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.2423) %, meaning that it generated substantial loss on money invested by shareholders. XSpray Pharma's management efficiency ratios could be used to measure how well XSpray Pharma manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Marie Moberg | Moberg Pharma AB | N/A | |
| Cecilia Hofvander | BioInvent International AB | 56 | |
| Sylvie Ryckebusch | BioInvent International AB | N/A | |
| Marie Svensson | Alligator Bioscience AB | 59 | |
| Mark Beveridge | Moberg Pharma AB | 45 | |
| Pr MD | Oncopeptides AB | N/A | |
| Malin Carlsson | Alligator Bioscience AB | 55 | |
| MSc BA | Moberg Pharma AB | 43 | |
| MSc MD | Oncopeptides AB | N/A | |
| Gunilla Wengstrm | Moberg Pharma AB | N/A | |
| Bjrn Frendus | BioInvent International AB | 50 | |
| Kristina Luthman | Oncopeptides AB | N/A | |
| Kerstin Strinnholm | Moberg Pharma AB | 63 | |
| Annika MBA | Oncopeptides AB | 57 | |
| Sren Bregenholt | Alligator Bioscience AB | 52 | |
| Anders Broijersen | Moberg Pharma AB | N/A | |
| Peter Nygren | Oncopeptides AB | 64 | |
| Ingrid Teige | BioInvent International AB | N/A | |
| MSc MSc | Oncopeptides AB | 53 | |
| Linda Holmstrom | Oncopeptides AB | N/A | |
| Jakob Lic | Oncopeptides AB | 51 | |
Management Performance
| Return On Equity | -0.24 | |||
| Return On Asset | -0.14 |
XSpray Pharma AB Leadership Team
Elected by the shareholders, the XSpray Pharma's board of directors comprises two types of representatives: XSpray Pharma inside directors who are chosen from within the company, and outside directors, selected externally and held independent of XSpray. The board's role is to monitor XSpray Pharma's management team and ensure that shareholders' interests are well served. XSpray Pharma's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, XSpray Pharma's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Kerstin Hasselgren, Chief Officer | ||
| Per Andersson, Chief Officer | ||
| Charlotta Liljebris, VP RD | ||
| Andreas Konar, Sr Devel | ||
| Thomas Walz, Chief Officer | ||
| AnnaKarin Ekberg, VP Sales | ||
| Christina Hagerstrand, VP Relations | ||
| Grald Jesson, VP Operations | ||
| Mustafa Demirbker, CoFounder Director |
XSpray Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is XSpray Pharma a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.24 | |||
| Return On Asset | -0.14 | |||
| Operating Margin | (116.51) % | |||
| Current Valuation | 1.16 B | |||
| Shares Outstanding | 22.68 M | |||
| Shares Owned By Insiders | 47.42 % | |||
| Shares Owned By Institutions | 27.60 % | |||
| Price To Book | 2.35 X | |||
| Price To Sales | 1,206 X | |||
| Gross Profit | 656 K |
Thematic Opportunities
Explore Investment Opportunities
Other Information on Investing in XSpray Stock
XSpray Pharma financial ratios help investors to determine whether XSpray Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in XSpray with respect to the benefits of owning XSpray Pharma security.